REGN SignalReason for this trade
1: Market is taking pullback from trendline
2: market is near high supply area
20,600.00
0.00 BRL
19.75 B BRL
65.52 B BRL
About Regeneron Pharmaceuticals, Inc.
Sector
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
Founded
1988
ISIN
BRREGNBDR005
FIGI
BBG00P14K7Y9
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Displays a symbol's price movements over previous years to identify recurring trends.
REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050Yield to maturity
6.94%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030Yield to maturity
5.42%
Maturity date
Sep 15, 2030
Explore more bonds
Curated watchlists where REGN34 is featured.
